EP Patent

EP1651611A2 — Benzimidazole c-2 heterocycles as kinase inhibitors

Assigned to Bristol Myers Squibb Co · Expires 2006-05-03 · 20y expired

What this patent protects

Benzimidazole derivatives having the general formula (I) are provided. These compounds are useful as tyrosine kinase inhibitors, especially for the treatment of cancer.

USPTO Abstract

Benzimidazole derivatives having the general formula (I) are provided. These compounds are useful as tyrosine kinase inhibitors, especially for the treatment of cancer.

Drugs covered by this patent

Patent Metadata

Patent number
EP1651611A2
Jurisdiction
EP
Classification
—
Expires
2006-05-03
Drug substance claim
No
Drug product claim
No
Assignee
Bristol Myers Squibb Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.